Healthcare Stocks Alert: Exelixis, Inc. (EXEL), Aetna Inc (AET)


Exelixis, Inc. (NASDAQ:EXEL):

Stock’s Trading Stats:

Exelixis, Inc. (NASDAQ:EXEL) surged 1.25% Friday and closed at $4.05. The company’s market capitalization is at $935.73 Million with an average trading volume of 4.67 Million. The total number of Outstanding Shares Held by the company are 228.19 Million.

Recent Press Release:

Exelixis, Inc. (EXEL) a biopharmaceutical company, discovers, develops, and commercializes small molecule therapies for the treatment of cancer in the United States and the European Union. The company offers cabozantinib, an internally-discovered inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive and metastatic medullary thyroid cancer under the COMETRIQ brand name. It also focuses on developing cabozantinib as a treatment for patients with advanced renal cell carcinoma; and engages in a development program to explore the clinical potential of cabozantinib in additional tumor types, counting a phase 3 trial of cabozantinib in advanced hepatocellular carcinoma. In addition, the company develops cobimetinib, an inhibitor of MEK, which is in phase 3 pivotal trial evaluating in combination with vemurafenib in formerly untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAF V600 mutation. Exelixis, Inc. has partnershipand license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs.

Aetna Inc (NYSE:AET):

Stock’s Trading Stats:

Aetna Inc (NYSE:AET) closed at $113.72 Friday by showing an increase of 1.22%. The total number of outstanding shares held by the company are 349.60 Million with the total market capitalization of $40.24 billion. The number of shares traded on the last trading session are 2.15 Million.

Recent Press Release:

Aetna Inc (AET) on April 1, 2016 declared that Thomas J. Sabatino, Jr., has been named executive vice president and general counsel, effective April 25. Sabatino also will join Aetna’s Executive Committee, the company’s senior-most leadership team.

Sabatino joins Aetna from Hertz Global Holdings, Inc., where he served most recently as senior executive vice president, chief administrative officer and general counsel. He has also held leadership positions at Walgreen Co., United Airlines, Schering-Plough Corporation, and Baxter International Inc.

Sabatino succeeds William J. Casazza, who will continue to serve as a planned advisor to Aetna in connection with the company’s pending acquisition of Humana. Casazza will retire upon the close of the transaction. Casazza has served Aetna for 24 years, and he has been executive vice president and general counsel since 2005. He has assisted to drive the company toward its mission of building a healthier world through his business-driven legal advice and deep commitment to compliance and ethics. As a result of Casazza’s leadership, Aetna also has received national recognition for its support of Pro Bono legal services.